Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evonik Buys into BioTech Startup - Happi
Patents

Evonik Buys into BioTech Startup

GERMANY: Through its venture capital unit, Evonik has invested in start-up firm Numaferm and now holds a minority share in the biotechnology company. The investment in the Düsseldorf-based company was made as part of a seed financing round and also includes investments by High-Tech Gründerfonds, the Business Angels and Qiagen co-founders Detlev Riesner and Jürgen Schumacher, as well as the European Investment Fund.


“Peptides and their applications are highly interesting for our growth engines, health and care and specialty additives. In addition, Evonik has great competency in biotechnology. That makes Numaferm an outstanding strategic match for us,” said Bernhard Mohr, head of venture capital at Evonik. 


Numaferm has developed a technology platform that enables plannable biotechnological production of peptides at higher yields and at lower costs.


Initially, Numaferm plans to use the fresh capital to drive forward technological development and get the first products to market maturity.

Evonik plans to invest a total of €100 million in promising start-ups with innovative technologies and in leading specialized venture capital funds as part of its venture capital activities. Regional focuses are Europe, the US and Asia. Currently, Evonik holds stakes in 11 start-ups and eight funds.

Add us as a preferred source on Google

Get the latest Happi news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Happi Newsletters